Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase I combination trial of CUDC-101.

17 Aug 2011

Novel therapy shrinks tumors without collateral damage

A potential new option is beginning to emerge for patients with the fastest growing form of cancer in the United States, according to researchers at the University of Alabama at Birmingham.

10 Aug 2011

Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.

2 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Polaris Group today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients.

29 Jul 2011

Hepatitis on the rise

According to the World Health Organization (WHO), the battle is on to fight the rising numbers of hepatitis B cases. Medical experts are calling for global action to tackle the viruses that cause the liver disease hepatitis. The first worldwide estimates in drug users show 10 million have hepatitis C while 1.3 million have hepatitis B.

29 Jul 2011

OR models verify cost effectiveness of hepatitis B interventions

With hepatitis B infecting as many as 10% of people of Asian descent, operations researchers collaborated with a liver transplant surgeon to develop mathematical models that verified the cost effectiveness of hepatitis B interventions.

27 Jul 2011

Lipid-based nanocarrier can improve cancer treatments

Scientists seeking to improve cancer treatments have created a tiny drug transporter that maximizes its ability to silence damaging genes by finding the equivalent of an expressway into a target cell.

27 Jul 2011

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

26 Jul 2011

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S. This population-based study publishing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, found that metabolic syndrome significantly increases risk of developing these primary liver cancers.

22 Jul 2011

Metabolic syndrome linked to increased risk of primary liver cancers

22 Jul 2011

Sirtex reports 4Q sales growth of 23%

Sirtex Medical Limited (ASX:SRX) today said sales of SIR-Spheres® microspheres, it’s targeted radioactive treatment for inoperable liver cancer, grew 23% in the fourth quarter of the 2011 Financial Year compared with the same quarter last year. Full year dose sales grew 19.3% compared to a 14% growth the year before.

21 Jul 2011

French scientists publish paper on guidelines for drinking and relation of alcohol to cancer

A group of French scientists have published a paper in the Canadian Medical Association Journal (CMAJ) on guidelines for drinking and the relation of alcohol to cancer.

21 Jul 2011

USPTO issues patent for Mirna's tumor suppressor microRNAs

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed multiple patent claims related to the therapeutic application of several tumor suppressor microRNAs.

21 Jul 2011

Men more likely to succumb to cancer

According to a new analysis of 36 different types of tumors and blood cancers that affect both sexes, men are more likely than women to get and die of cancer. The report shows that leukemia and cancers of the colon and rectum, pancreas, and liver killed about one and a half to two times as many men as women in the U.S. over a 30-year period. Lung cancer killed nearly two and a half times as many men during that time. According to the American Cancer Society men have about a 1 in 2 chance of developing cancer at some point in their lives, compared with women, who have a 1 in 3 chance.

13 Jul 2011

New research strategy for eradicating HIV from the body

An international team led by researchers from the University of California, San Francisco and the nonprofit Vaccine and Gene Therapy Institute of Port St. Lucie, Fla., has received a major grant from the National Institutes of Health to develop a strategy to eradicate HIV from the body.

12 Jul 2011

BioAlliance receives European patent for Livatag to treat primary liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces the grant of a European patent protecting its Transdrug nanotechnology.

12 Jul 2011

NIAID awards $14 million a year for new HIV research

Three research teams focused on developing strategies that could help to rid the body of HIV are receiving grants totaling more than $14 million a year, for up to five years, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announced today.

11 Jul 2011

Inhibiting heat shock transcription factor 1 prevents liver cancer in mice

Altering the body's metabolism could be an effective treatment for deadly liver cancer, researchers report.

7 Jul 2011

New insight into tumor biology

Cancer cells are well known for their altered metabolisms, which may help them generate the energy they need for rapid growth. Using an emerging imaging technology, researchers reporting in the July Cell Metabolism, a Cell Press publication, have discovered that those metabolic shifts actually develop even before detectable tumors form.

6 Jul 2011